HCW Biologics

Q2 FY2026 EarningsQ2 FY2026 performance was mixed compared to consensus: while revenue of $0.14M beat the $0.00 expectation due to clinical license services, Net Loss of $5.22M was significantly wider than the $3.17M consensus. GAAP EPS of -$11.58 appears to beat the -$1.98 consensus, though this is primarily driven by a 1-for-6 reverse stock split and a substantial increase in weighted average shares from equity financing. Management issued a 'going concern' warning, emphasizing the critical need for additional funding despite raising $5.6M in recent private placements.